HealthDay - TUESDAY, March 22 (HealthDay News) -- The death rate of patients with chronic myeloid leukemia who took Gleevec and were in remission two years after treatment was similar to the death rate in the general population, a new study shows.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.